Literature DB >> 9714064

O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.

J Mattern1, U Eichhorn, B Kaina, M Volm.   

Abstract

The DNA repair protein O6-methylguanine-DNA methyl-transferase (MGMT) is a main determinant of resistance of cells to the cytostatic effects of O6-alkylguanine-generating alkylating agents. The purpose of our study was to assay MGMT activity in cells of lung cancers and to correlate MGMT levels with chemotherapy response to cyclophosphamide (CTX) and cisplatin (DDP). MGMT levels were determined in 14 human lung tumor xenografts. There was a wide variation of MGMT expression in these tumors, ranging from 10 to 984 fmol/mg protein. There was also a wide range in the sensitivity of the xenografts to CTX and DDP, as measured by specific growth delay. When the MGMT levels of the different xenograft lines were compared with the corresponding responses to CTX and DDP, a close correlation was found between MGMT activity and CTX (lin reg., r = -0.83, p < 0.05). The higher the MGMT activity, the less pronounced was the growth-inhibiting effect of CTX. With DDP, no such correlation was found. Our results indicate that the in vivo response of tumors to CTX is related to the level of MGMT expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714064     DOI: 10.1002/(sici)1097-0215(19980911)77:6<919::aid-ijc20>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.

Authors:  Toshihito Ohno; Junji Hiraga; Haruhiko Ohashi; Chiho Sugisaki; Eika Li; Haruhiko Asano; Tastuya Ito; Hirokazu Nagai; Yoriko Yamashita; Naoyoshi Mori; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

3.  Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding.

Authors:  D S Daniels; C D Mol; A S Arvai; S Kanugula; A E Pegg; J A Tainer
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

4.  The significance of MGMT protein detection in evaluation of osteosarcoma necrosis rate after cisplatin chemotherapy.

Authors:  Qiu Cui; Dingfeng Li; Cheng Liu; Jun Guo; Shubin Liu; Yaosheng Liu; Xiaohong Wang; Yanjun Zeng
Journal:  Bosn J Basic Med Sci       Date:  2011-05       Impact factor: 3.363

5.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

6.  Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.

Authors:  Ramamoorthy Nagasubramanian; Ryan J Hansen; Shannon M Delaney; Mathew M Cherian; Leona D Samson; Scott C Kogan; M Eileen Dolan
Journal:  Mutagenesis       Date:  2008-05-13       Impact factor: 3.000

7.  Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.

Authors:  Jin Ren; Rui Wang; Haizhu Song; Guichun Huang; Longbang Chen
Journal:  Mol Med       Date:  2014-04-08       Impact factor: 6.354

8.  O6-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy.

Authors:  Sayuri Isono; Makoto Fujishima; Tatsuya Azumi; Yukihiko Hashimoto; Yoshifumi Komoike; Masao Yukawa; Masahiro Watatani
Journal:  Oncol Lett       Date:  2014-03-20       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.